Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® Over Five Years
CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering
Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines
CSL Behring Signs Letter of Intent with pan-Canadian Pharmaceutical Alliance for Public Reimbursement of HEMGENIX® , the First Gene Therapy for Hemophilia B
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
New Found Gold Continues to Confirm Continuity of At-Surface High-Grade Gold at Keats Zone, Queensway Gold Project
